Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.

Arteriosclerosis, thrombosis, and vascular biology - 1 May 2024

Raal Frederick J, Hegele Robert A, Ruzza Andrea, López J Antonio G, Bhatia Ajay K, Wu Johnny, Wang Huei, Gaudet Daniel, Wiegman Albert, Wang Jian, Santos Raul D

Abstract excerpt

BACKGROUND: Pediatric patients with homozygous familial hypercholesterolemia (HoFH) have an increased risk of atherosclerotic cardiovascular disease and difficulty meeting low-density lipoprotein cholesterol (LDL-C) goals. In this post hoc analysis, we evaluated pooled safety and efficacy data from 3 studies in pediatric patients with HoFH treated with the PCSK9 (proprotein convertase subtilisin/kexin type 9)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Anticholesteremic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, LDL

Share to Ezetimibe

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hyperlipoproteinemia Type II

Share to Proprotein Convertase 9

Share to Serine Proteinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 38545781
DOI: 10.1161/ATVBAHA.123.320268
PMCID: PMC11042515

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.PMID 38545781Read ↗

Evolocumab in Pediatric Heterozygous Familial HypercholesterolemiaSemantic proximity Read ↗

Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia.Semantic proximity Read ↗

Evolocumab in patients with homozygous familial hypercholesterolemia in India.Semantic proximity Read ↗

Successful pharmacological management of a child with compound heterozygous familial hypercholesterolemia and review of the recent literature.Semantic proximity Read ↗

Real-world management of familial hypercholesterolemia in paediatric patients: a 3-year follow-up from the LIPIGEN registry.Semantic proximity Read ↗

Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized TrialSemantic proximity Read ↗

Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations.Semantic proximity Read ↗

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.Semantic proximity Read ↗

Knowns and unknowns in the care of pediatric familial hypercholesterolemiaSemantic proximity Read ↗

Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children.Semantic proximity Read ↗

Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.Semantic proximity Read ↗

Analysis of Children and Adolescents with Familial Hypercholesterolemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.